Skip to main content
Clinical Trials/NCT01057849
NCT01057849UnknownNot Applicable

Sequenced Atypical Antipsychotics Therapy With Intensive or Basic Psychosocial Intervention for First-episode Schizophrenia: An Effectiveness Study

Peking University6 sites in 1 country600 target enrollmentStarted: September 2008Last updated:
Conditions
Interventions
Drugs

Trial Snapshot

Phase
Not Applicable
Sponsor
Enrollment
600
Locations
6
Primary Endpoint
the time the patients remain stable

Study Overview

Brief Summary

Schizophrenia is not a curable but a treatable disease by antipsychotics. Kinds of atypical antipsychotics are widely used since 1990s' in China. Although their efficacy for acute phase are all better than typicals, individulized regimen of them for first-episode schizophrenia and their effectiveness in real naturalistic clinical settings still remain unclear. And those patients also need more comprehensive intervention such as psychosocial programs to improve their function. This protocol is to conduct a study in several sites of China to investigate the effectiveness of comprehensive intervention combining sequenced atypical antipsychotic therapy and intensive psychosocial intervention for first-episode schizophrenic patients. In addition, this protocol also aims at collecting such information as molecular genetics, neurochemical test, neucognitive performance and neuroimaging for outcome analysis.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
16 Years to 45 Years (Child, Adult)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • schizophrenic patients diagnosed with DSM-IV criteria by SCID-I.
  • age between 16-45 years old
  • with disease course less than 3 years and during their first episode
  • without receiving systematic antipsychotic treatment less than 1 month

Exclusion Criteria

  • organic disease or unstable physical diseases.
  • brain trauma with loss of consciousness more than 1 hour
  • current substance misuse (in 3 months) or any substance dependence.
  • pregnant women.
  • patients with severe suicidal imaginations or behavior.
  • mental retardation
  • contradict to the study drugs

Arms & Interventions

Risperidone, Intensive

Experimental

risperidone and intensive psychosocial intervention

Intervention: risperidone (Drug)

risperidone, basic

Active Comparator

risperidone and basic psychosocial support

Intervention: risperidone (Drug)

olanzapine, intensive

Experimental

olanzapine and intensive psychosocial intervention

Intervention: olanzapine (Drug)

olanzapine, basic

Active Comparator

olanzapine and basic psychosocial support

Intervention: olanzapine (Drug)

aripiprazole, intensive

Experimental

aripiprazole and intensive psychosocial intervention

Intervention: Aripiprazole (Drug)

aripiprazole, basiv

Active Comparator

aripiprazole and basic psychosocial support

Intervention: Aripiprazole (Drug)

Outcomes

Primary Outcomes

the time the patients remain stable

Time Frame: 1 year

Secondary Outcomes

  • Scoring of PANSS and PSP(1 year)

Investigators

Sponsor
Peking University
Sponsor Class
Other

Study Sites (6)

Loading locations...

Similar Trials